A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses followed by a 2nd dose of the RSV vaccine to Healthy non-Pregnant Women

Trial Identifier: 209141
Sponsor: GlaxoSmithKline
Start Date: November 2019
Primary Completion Date: February 2020
Study Completion Date: November 2021
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Gent, Belgium, 9000
Belgium Leuven, Belgium, 3000
Canada, Nova Scotia Truro, Nova Scotia, Canada, B2N 1L2
Canada, Ontario London, Ontario, Canada, N5W 6A2
United States, Florida Miami, Florida, United States, 33143
United States, Kansas Lenexa, Kansas, United States, 66219
United States, New York Rochester, New York, United States, 14609
United States, Washington Seattle, Washington, United States, 98105